ReviewMicromachines2026
Molecularly Imprinted Polymers for Biosensing: From Synthetic Recognition to Integrated Biointerfaces.
Review in Micromachines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted polymers (MIPs) are synthetic receptors with cavities shaped around a template, combining antibody-like selectivity with chemical, thermal, and mechanical robustness; low cost; and reusability. This Review examines recent advances in MIP-based biosensing, from bulk materials to thin-film, nanostructured, surface-imprinted, and epitope-imprinted architectures designed to improve site accessibility and performance in complex biofluids. We connect polymer chemistry and interface design to molecular recognition and electrochemical, optical, and mass-sensitive transduction. Applications range from small molecules, proteins, nucleic acids, and viruses to whole cells, encompassing miniaturized, wearable, and point-of-care formats. Particular attention is devoted to design assisted by computational methods and machine learning, as well as to the challenges of reproducibility, standardization, metrology, and sustainability that still limit translation. Rather than universal substitutes for antibodies, MIPs are presented as programmable biointerfaces that integrate molecular recognition, signal transduction, device engineering, and the design of low-environmental-impact materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.